estriol has been researched along with Female Genitourinary Diseases in 13 studies
hormonin: estrogen replacement; each tablet contains 600 ug micronized 17beta-estradiol, 270 ug estriol and 1.4 mg estrone
chlorapatite : A phosphate mineral with the formula Ca5(PO4)3Cl.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The objective of this prospective comparative cohort study was to establish the effectiveness and safety of Erbium:YAG (Er:YAG) laser treatment for genitourinary syndrome of menopause and to compare it with an established topical estriol treatment." | 9.24 | Efficacy of Erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause. ( Brandi, H; Gaspar, A; Gomez, V; Luque, D, 2017) |
| "The significant decline in gonadotropin levels, indicating systemic effects, has to be kept in mind when offering vaginal estriol to breast cancer patients receiving an aromatase inhibitor." | 9.15 | Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. ( Fink-Retter, A; Geisendorfer, T; Glatz, C; Königsberg, R; Kubista, E; Pfeiler, G; Seifert, M; Singer, CF, 2011) |
| "To evaluate the efficacy and safety of estriol for the treatment of vulvovaginal atrophy in postmenopausal women." | 8.95 | The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review. ( Avellaneda, AC; Osorio, AM; Pinzón, CE; Restrepo, OI; Rueda, C, 2017) |
| "This study evaluates the effect of intravaginal estriol on urogenital atrophy, Pap smear parameters, colposcopy parameters and discomfort during gynecological examination." | 7.77 | Efficacy of vaginal use of topical estriol in postmenopausal women with urogenital atrophy. ( Belfort, PN; Chuery, AC; de Moura, KF; Ribalta, JC; Sakano, C; Speck, NM, 2011) |
| "The objective of this prospective comparative cohort study was to establish the effectiveness and safety of Erbium:YAG (Er:YAG) laser treatment for genitourinary syndrome of menopause and to compare it with an established topical estriol treatment." | 5.24 | Efficacy of Erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause. ( Brandi, H; Gaspar, A; Gomez, V; Luque, D, 2017) |
| "The significant decline in gonadotropin levels, indicating systemic effects, has to be kept in mind when offering vaginal estriol to breast cancer patients receiving an aromatase inhibitor." | 5.15 | Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients. ( Fink-Retter, A; Geisendorfer, T; Glatz, C; Königsberg, R; Kubista, E; Pfeiler, G; Seifert, M; Singer, CF, 2011) |
| "To evaluate the efficacy and safety of estriol for the treatment of vulvovaginal atrophy in postmenopausal women." | 4.95 | The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review. ( Avellaneda, AC; Osorio, AM; Pinzón, CE; Restrepo, OI; Rueda, C, 2017) |
| "This study evaluates the effect of intravaginal estriol on urogenital atrophy, Pap smear parameters, colposcopy parameters and discomfort during gynecological examination." | 3.77 | Efficacy of vaginal use of topical estriol in postmenopausal women with urogenital atrophy. ( Belfort, PN; Chuery, AC; de Moura, KF; Ribalta, JC; Sakano, C; Speck, NM, 2011) |
| "The syndrome is underreported and undertreated in Norway." | 1.28 | [Urogenital estrogen deficiency syndrome. Investigation and treatment with special reference to hormone substitution]. ( Eriksen, BC; Hunskår, S, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (61.54) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rueda, C | 1 |
| Osorio, AM | 1 |
| Avellaneda, AC | 1 |
| Pinzón, CE | 1 |
| Restrepo, OI | 1 |
| Matarazzo, MG | 1 |
| Caruso, S | 1 |
| Giunta, G | 1 |
| Valenti, G | 1 |
| Sarpietro, G | 1 |
| Cianci, A | 1 |
| Gaspar, A | 1 |
| Brandi, H | 1 |
| Gomez, V | 1 |
| Luque, D | 1 |
| Pfeiler, G | 1 |
| Glatz, C | 1 |
| Königsberg, R | 1 |
| Geisendorfer, T | 1 |
| Fink-Retter, A | 1 |
| Kubista, E | 1 |
| Singer, CF | 1 |
| Seifert, M | 1 |
| Chuery, AC | 1 |
| Speck, NM | 1 |
| de Moura, KF | 1 |
| Belfort, PN | 1 |
| Sakano, C | 1 |
| Ribalta, JC | 1 |
| Koloszár, S | 1 |
| Kovács, L | 1 |
| Di Stefano, L | 1 |
| Patacchiola, F | 1 |
| Moscarini, M | 1 |
| Lisper, B | 1 |
| Nordenstam, I | 1 |
| Wessling, A | 1 |
| Smetnik, VP | 1 |
| Heimer, GM | 1 |
| Englund, DE | 1 |
| Foidart, JM | 1 |
| Vervliet, J | 1 |
| Buytaert, P | 1 |
| Eriksen, BC | 1 |
| Hunskår, S | 1 |
| Molander, U | 1 |
| Milsom, I | 1 |
| Ekelund, P | 1 |
| Mellström, D | 1 |
| Eriksson, O | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Fractional / Pixel CO2 Laser Treatment of Vulvar Atrophy and Lichen Sclerosus[NCT03063684] | 16 participants (Actual) | Interventional | 2017-09-01 | Completed | |||
| Effectiveness of C02 Microfractionated Laser in Conjunction With Topical Regenerative Therapy in the Management of Vulvo-vaginal Atrophy in Patients With a History of Breast Cancer. Randomized Experimental and Comparative Study.[NCT05585476] | 98 participants (Anticipated) | Interventional | 2022-12-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for estriol and Female Genitourinary Diseases
| Article | Year |
|---|---|
The efficacy and safety of estriol to treat vulvovaginal atrophy in postmenopausal women: a systematic literature review.
Topics: Administration, Intravaginal; Adult; Aged; Aged, 80 and over; Atrophy; Endometrium; Estriol; Female; | 2017 |
6 trials available for estriol and Female Genitourinary Diseases
| Article | Year |
|---|---|
Efficacy of Erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause.
Topics: Administration, Topical; Estriol; Female; Female Urogenital Diseases; Humans; Laser Therapy; Lasers, | 2017 |
Efficacy of Erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause.
Topics: Administration, Topical; Estriol; Female; Female Urogenital Diseases; Humans; Laser Therapy; Lasers, | 2017 |
Efficacy of Erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause.
Topics: Administration, Topical; Estriol; Female; Female Urogenital Diseases; Humans; Laser Therapy; Lasers, | 2017 |
Efficacy of Erbium:YAG laser treatment compared to topical estriol treatment for symptoms of genitourinary syndrome of menopause.
Topics: Administration, Topical; Estriol; Female; Female Urogenital Diseases; Humans; Laser Therapy; Lasers, | 2017 |
Vaginal estriol to overcome side-effects of aromatase inhibitors in breast cancer patients.
Topics: Administration, Intravaginal; Aromatase Inhibitors; Breast Neoplasms; Chromatography, Gas; Drug Moni | 2011 |
[Transvaginal administration of estriol in postmenopausal urogynecological disorders].
Topics: Dose-Response Relationship, Drug; Estriol; Female; Female Urogenital Diseases; Genital Diseases, Fem | 1993 |
Effects of vaginally-administered oestriol on post-menopausal urogenital disorders: a cytohormonal study.
Topics: Administration, Intravaginal; Aged; Aged, 80 and over; Atrophy; Bacteriuria; Epithelium; Estriol; Fe | 1992 |
Efficacy of sustained-release vaginal oestriol in alleviating urogenital and systemic climacteric complaints.
Topics: Administration, Intravaginal; Adult; Aged; Biopsy; Climacteric; Double-Blind Method; Estriol; Female | 1991 |
Effect of oral oestriol on vaginal flora and cytology and urogenital symptoms in the post-menopause.
Topics: Administration, Oral; Aged; Bacteria; Double-Blind Method; Estriol; Female; Female Urogenital Diseas | 1990 |
6 other studies available for estriol and Female Genitourinary Diseases
| Article | Year |
|---|---|
Does vaginal estriol make urodynamic changes in women with overactive bladder syndrome and genitourinary syndrome of menopause?
Topics: Aged; Aged, 80 and over; Drug Administration Schedule; Estriol; Estrogens; Female; Female Urogenital | 2018 |
Efficacy of vaginal use of topical estriol in postmenopausal women with urogenital atrophy.
Topics: Administration, Intravaginal; Aged; Atrophy; Estriol; Female; Female Urogenital Diseases; Humans; Mi | 2011 |
[Treatment of climacteric urogenital disorders with an estriol-containing ointment].
Topics: Administration, Topical; Aged; Aged, 80 and over; Atrophy; Cystitis; Epithelium; Estriol; Female; Fe | 1995 |
[Urogenital estrogen deficiency symptoms. Too few elderly women receive any treatment].
Topics: Aged; Drug Prescriptions; Drug Utilization; Estriol; Estrogen Replacement Therapy; Estrogens; Female | 1993 |
[Principles of hormone replacement therapy in climacteric].
Topics: Aged; Aged, 80 and over; Cardiovascular Diseases; Climacteric; Estradiol; Estriol; Estrogen Replacem | 1997 |
[Urogenital estrogen deficiency syndrome. Investigation and treatment with special reference to hormone substitution].
Topics: Aged; Atrophy; Estriol; Estrogen Replacement Therapy; Estrogens; Female; Female Urogenital Diseases; | 1991 |